On Thursday, Merck & Co (MRK.N) said it would buy Acceleron Pharma Inc (XLRN.O) for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue. The deal gives Merck access to Acceleron's rare disease drug candidate, sotatercept, which the company